ArthritoMab™ Case study
25 preclinical studies, 18 months, 1 out licensed compound With the number of blockbuster drugs approaching patent expiration and pharma companies struggling to maintain pipeline and portfolios with in-house programs, companies are increasingly turning to licensing, aquisitions and partnerships. Early-stage licensing deals tend to carry more risk for pharma companies..
Read more